EXTENDED REPORT

Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis

R Nissinen, M Leirisalo-Repo, R Peltomaa, T Palosuo, O Vaarala


The inflamed synovium of patients with rheumatoid arthritis (RA) is characterised by massive leucocytic infiltration, mainly consisting of macrophages, T lymphocytes, and plasma cells. These cells express many proinflammatory cytokines, chemokines, and growth factors and are considered responsible for the degradation of the cartilage and erosion of juxta-articular bone.1,2

Tumour necrosis factor α (TNFα) is expressed mainly by cells of the macrophage/monocyte lineage and is the most abundant and rapidly produced proinflammatory cytokine in the rheumatoid joint. It has a central role in regulation of the synthesis and function of proinflammatory molecules and is involved in the recruitment of immune cells infiltrating into the joints.3

Treatment with agents blocking the function of TNFα has proved to be highly effective in RA. To date there are two blocking agents in clinical use, a soluble TNFα receptor, etanercept, and a monoclonal antibody, infliximab.1,4

The mechanisms behind the clinical effect of TNFα blocking treatment are not fully understood. TNFα blocking by antibodies or soluble receptors reduces the expression of vascular adhesion molecules5 and inhibits the spontaneous production of interleukin (IL)1 and IL6 in an animal model.6 Within days after starting infliximab treatment serum IL6 levels fall to normal and C reactive protein (CRP), primarily controlled by IL6, normalises.5,6 In patients with RA also an increase in the production of interferon γ (IFNγ) by lymphocytes has been reported after treatment with soluble TNFα receptor.11 At the same time, reduction in the homing of lymphocytes to the joints is seen.

TNFα also participates in the formation of new blood vessels in the rheumatoid joint. This not only enables enhanced delivery of inflammatory cells and mediators to the joint but also creates an invasive property of pannus at the cartilage and bone junction. Blocking of TNFα reduces the raised concentrations of serum vascular endothelial growth factor12 detected in patients with RA and reduces angiogenesis. However, the immediate immunological mechanisms resulting from the blocking of TNFα are crucial because clinical improvement is seen in days after the start of treatment.

To study the mechanisms in the TNFα blockade we examined the expression of chemokine receptors (CCR3, CCR5), and the secretion of IL4, IL5, IFNγ, and TNFα in peripheral blood T cells and monocytes of patients with active RA or other arthritides during early treatment with infliximab. The mRNA expression of IFNγ, IL4, IL5, and TNFα in peripheral blood mononuclear cells (PBMC) was assessed with real time reverse transcriptase-polymerase chain reaction (RT-PCR). We also followed the changes in plasma levels of acute phase reactants, such as CRP, serum amyloid protein A (SAA), rheumatoid factor (RF), antiflaggrin antibodies (AFA), and antibodies to flaggrin derived cyclic citrullinated peptide (aCCP).
Patiets and Methods

Patients
We studied 25 patients with active RA who had not responded to conventional treatment with disease modifying antirheumatic drugs (DMARDs), including methotrexate, and five patients with other chronic active joint diseases (two patients with psoriatic arthritis, one with chronic reactive arthritis, one with spondyloarthropathy, and one with juvenile idiopathic arthritis) in whom treatment with infliximab was started. At the time of examination, all patients were using varying antirheumatic drugs either as a single DMARD or in different combinations. Twenty one patients with RA and four patients with other arthritides were receiving low dose (<10 mg/day) prednisone. Table 1 presents the characteristics of the patients.

In the patients with RA the response to infliximab was evaluated at week 2 by calculating the American College of Rheumatology (ACR) response in (two patients the information was available only at week 6). Patients with an improvement of at least 20% (ACR20) were considered to be responders. Fifteen patients with RA were considered to be responders, 10 non-responders.

Nine healthy people matched for age and sex were studied as controls.

Cell extraction
EDTA-blood was collected from the patients immediately before the infusions of infliximab (3 mg/kg) at the start and at 2 and 6 weeks during the treatment. EDTA-blood was taken at 2 week intervals from healthy controls. PBMC were isolated by Ficoll gradient centrifugation. The cells were then washed three times with pyrogen free phosphate buffered saline (PBS) and suspended in a concentration of 5×10^6 cells/ml in RPMI medium containing 5% AB serum, 25 mM Hepes, 2 mM glutamine, and 25 mg/ml gentamicin.

Fluorescence activated cell sorter (FACS) for chemokine receptor analysis
PerCP conjugated antihuman CD3, FITC conjugated antihuman CD8 and CD14, and PE conjugated antihuman IFNγ and IL4 antibodies and isotype control and leucogate were purchased from Becton Dickinson (BD, Erembodegem, Belgium). PE conjugated antihuman CCR3 and CCR5 antibodies were purchased from R&D (Abingdon, UK).

Ex vivo PB derived cells were washed with PBS containing 0.5% bovine serum albumin (BSA) and suspended in a concentration of 2×10^6 cells/ml in RPMI medium containing 5% AB serum, 25 mM Hepes, 2 mM glucose, and 25 μg/ml gentamicin.

Table 1 Characteristics of the patients

<table>
<thead>
<tr>
<th>Demographics</th>
<th>Rheumatoid arthritis (n = 25)</th>
<th>Arthritis controls (n = 5)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years), mean (range)</td>
<td>55 (34–76)</td>
<td>38 (22–56)</td>
</tr>
<tr>
<td>Sex (female/male)</td>
<td>19/6</td>
<td>0/5</td>
</tr>
<tr>
<td>Disease duration (years), mean (range)</td>
<td>13 (3–32)</td>
<td>9.4 (1–16)</td>
</tr>
<tr>
<td>RF (No positive)</td>
<td>20</td>
<td>1</td>
</tr>
<tr>
<td>Swollen joint count, mean (range)</td>
<td>17 (6–38)</td>
<td>11 (0–30)</td>
</tr>
<tr>
<td>Tender joint count, mean (range)</td>
<td>21 (2–41)</td>
<td>11 (1–24)</td>
</tr>
<tr>
<td>Patient’s global assessment (mm), mean (range)</td>
<td>7.3 (2.5–10.2)</td>
<td>7 (5.6–9)</td>
</tr>
<tr>
<td>Physician’s global assessment (mm), mean (range)</td>
<td>6.8 (3.8–10.2)</td>
<td>6.7 (4.6–9)</td>
</tr>
<tr>
<td>ESR (mm/1st h), mean (range)</td>
<td>30 (10–108)</td>
<td>70 (16–104)</td>
</tr>
<tr>
<td>C reactive protein (mg/l), mean (range)</td>
<td>83 (5–272)</td>
<td>28.5 (6.7–92)</td>
</tr>
<tr>
<td>S-amyloid protein A (mg/l), mean (range)</td>
<td>226 (14.5–495)</td>
<td>199 (20–303)</td>
</tr>
</tbody>
</table>

*95% of healthy blood donors have values below 2 mg/l; 195% of healthy blood donors have values below 7.5 mg/l

The results were expressed as the percentage of cells staining positive for different markers. The cut off point for positive staining for intracellular cytokines and chemokine receptors is above the level of the control isotype antibody.

Cell stimulation
Ficoll isolated cells were stimulated in a concentration of 2×10^6 cells in 200 μl volume with 5 μg/ml phytohaemagglutinin (PHA) for 24 hours in U bottomed plates at 37°C. Supernatants and cells were collected 24 hours after the stimulation and analysed further.

Enzyme linked immunosorbent assay (ELISA) for IFNγ, IL5, IL4, and TNFα
For detection of IFNγ, 96 well microtitre plates (Maxisorb, Nunc, Roskilde, Denmark) were coated with monoclonal antihuman IFNγ antibody (clone 2G1; Endogen, Woburn, MA) at a concentration of 2 μg/ml (50 μl/well) and incubated overnight at 4°C. After washing with PBS containing 0.05% Tween (PBS-T), the plates were blocked with 1% BSA in PBS for 30 minutes. Dilutions of recombinant human IFNγ (catalogue No 19751N; Pharmingen, San Diego, CA) were used to create a standard curve. Supernatant samples and standards were incubated for 2 hours. After washing with PBS-T, biotinylated antihuman IFNγ monoclonal antibody (clone B133.5; Endogen) was added at a concentration of 0.5 μg/ml (50 μl/well) and the plates were incubated for 1.5 hours. After washing with PBS-T, streptavidin-alkaline phosphatase complex (Zymed, San Francisco, CA) was added for 30 minutes’ incubation. β-Nitrophenyl phosphate (Medix, Kauniainen, Finland) was used to develop the colour for reading at 405 nm. The concentration of IFNγ secreted into the supernatants of unstimulated cells was subtracted from that of the stimulated cells. The detection level of the assay was 50 pg/ml.

Measurement of IL5 was performed according to the protocol used for IFNγ. Purified rat antihuman IL5 (1 μg/ml; clone TRFK3, Pharmingen) was used as primary antibody and biotinylated rat antihuman IL5 (0.5 μg/ml; clone JES5A10, Pharmingen) as secondary antibody. Dilutions of recombinant human IL5 (catalogue No 19651V, Pharmingen) were used to create the standard curve. The detection level for IL5 was 30 pg/ml.

IL4 was measured from the supernatants by PeliKine Compact human IL4 ELISA kit (catalogue No M1914; CLB,
Amsterdam, Netherlands) and TNFα by human TNFα ELISA kit (catalogue No 1425 943; Roche Diagnostics, Mannheim, Germany), according to the instructions of the manufacturer. The concentration of cytokine secreted into the supernatants of unstimulated cells was subtracted from that of the stimulated cells. The detection level of the kit for IL4 was 2 pg/ml and for TNFα 20pg/ml.

**ELISA for CRP, SAA, and IgM RF**

CRP, SAA, and IgM RF were detected in plasma according to the manufacturer’s protocol with CRP ELIA kit (Eucardo Laboratory, Inc, San Diego, CA, USA), Cytoscreen human SAA (Biosource International, Camarillo, CA, USA), and QuantaLite RF IgM ELISA (INOVA Diagnostics, Inc, San Diego, CA, USA), respectively.

**ELISA for antifilaggrin antibodies**

The extraction and purification of filaggrin from human skin was effected and used as an antigen in an ELISA as previously described. 14

**ELISA for aCCP**

Cyclic citrullinated peptide (CCP; cfc1-cyc), described by Schellekens et al, was used as the antigen. The peptide was synthesised, cyclised, and purified by high performance liquid chromatography at the Institute of Biotechnology, University of Helsinki (Dr C Kantor-Aaltonen).

CCP at a concentration of 1 µg/ml in 50 mM ammonium bicarbonate buffer, pH 9.6, was applied onto 96 well microtitre plates (100 µl/well; EXICON, Peptide immobiliser). The plates were incubated overnight at 4°C. The wells were then emptied and washed three times with PBS-T. Human serum samples (100 µl), diluted 1:200 in PBS-T containing 0.2% human serum albumin (Finnish Red Cross Blood Transfusion Service, Helsinki, Finland), were then applied onto the plates and incubated at room temperature for 1.5 hours. After the incubation the wells were rinsed three times with PBS-T, and 100 µl of alkaline phosphatase conjugated rabbit antihuman IgG (Jackson Immuno-research, West Grove Pa, USA) diluted 1:1000 in PBS-T was added and incubated for 1 hour at room temperature. After rinsing the wells three times with PBS-T, the substrate (p-nitrophenyl phosphate; Sigma, St Louis, Mo, USA), 1 mg/ml in 50 mM carbonate buffer, pH 9.8, was added. The development colour was read at 405 nm.

**Real time reverse transcriptase-polymerase chain reaction (RT-PCR)**

The mRNA expression of cytokines and chemokine receptors was detected by real time RT-PCR from unstimulated and PHA stimulated cells.

Total RNA (tRNA) was extracted from frozen cells stored at −70°C in the lysis buffer of RNA Total Gen Elute Mammalian RNA kit. The reverse transcription reaction was carried out in a final volume of 20 µl by using TaqMan Reverse Transcription Reagents (Applied Biosystems, Foster City, CA, USA). The solution was treated with 0.01 U/µl DNase (Boehringer Mannheim) before adding the Multiscribe Reverse Transcriptase-enzyme (1.25 U/µl).

Real Time PCR was performed using an automated fluorometer, ABI Prism 7700 Sequence Detection System (Applied Biosystems), and TaqMan PDAR (pre-developed assay reagents) primers/probes. PDAR primers/probes for TNFα (catalogue No 4327055F), IL4 (catalogue No 4327038), and IFNγ (catalogue No 4327052) were used. Ribosomal 18S (catalogue No 4310893E) was used as endogenous control. The PCR reactions were run in triplicate wells with 5 ng of each cDNA. The expression of each cytokine was measured also from a home made calibrator sample, which was prepared from PHA stimulated PBMC of a healthy subject.

We used the comparative Ct method to measure the gene transcription in samples. The Ct of 18S was subtracted from the cytokine Ct. This difference was the ΔCt value. The ΔCt of the analysed sample was then subtracted from the ΔCt of the calibrator. This difference is called the ΔΔCt value. The results are expressed as relative units based on calculation of 2−△△Ct, which gives the relative amount of cytokine normalised to endogenous control (18S) and compared with calibrator.

**Statistics**

A comparison of variables between the different follow up samples was carried out with the Wilcoxon signed ranks test. We used the Mann-Whitney test for comparison of two groups. A p value <0.05 was considered significant.

**RESULTS**

**Cytokine and chemokine receptor profile at entry**

At entry, patients with RA and patients with other arthritides showed a lower secretion of IFNγ than controls (median 1513 ν 11 970 pg/ml, p<0.0001 and median 375 ν 11 970 pg/ml, p = 0.004, for patients with RA and other arthritides, respectively; ranges were 0–18 700 pg/ml for RA, 0–7370 pg/ml for other arthritides, 6788–32 080 pg/ml for healthy controls). Also, the ratio of IFNγ/IL4 mRNA of PHA stimulated PBMC was lower in RA and in other arthritides than in controls (median 0.2 ν 1.7, p = 0.003 and median 0.0 ν 1.7, p = 0.004, for patients with RA and other arthritides, respectively; ranges 0–13 for RA, 0–0.3 for other arthritides, 0–7 for healthy controls). Patients with RA also had a lower number of monocytes expressing CCR3 than controls (median 1 ν 2.4, p = 0.009; ranges 0–5 for RA, 1–7 for healthy controls). Patients with other arthritides did not differ in the number of monocytes expressing CCR3 (data not shown).

In patients with other arthritides a lower expression of TNFα mRNA was noted than in controls (median 222 ν 645, p = 0.002; ranges 0–338 for other arthritides, 270–1701 for healthy controls). Such a difference was not seen between controls and patients with RA (data not shown).

No differences between patient and control groups were seen in the number of T cells expressing CCR3 or CCR5, in the mitogen stimulated secretion of TNFα or IL4, or in the number of monocytes expressing CCR5.

**Changes in autoantibodies and serum markers for inflammation during infliximab treatment**

In patients with RA the plasma CRP and SAA levels had decreased by 2 weeks after the first TNFα infusion (median 45 v 6 µg/ml, range 5–272 µg/ml before treatment and 1–276 µg/ml 2 weeks after, p<0.0001 for CRP; and median 236 ν 40 ng/ml, range 14.5–493 ng/ml before treatment and 4–473 ng/ml 2 weeks after, p<0.0001 for SAA) and were still significantly lower after 6 weeks’ follow up when compared with the levels measured before treatment (median 45 v 7 µg/ml, range 5–272 µg/ml before treatment and 1–93 µg/ml 6 weeks after, p<0.0001 for CRP; and median 236 ν 30 ng/ml, range 14–495 ng/ml before treatment and 7–268 ng/ml 6 weeks after, p<0.0001 for SAA).

In patients with other arthritides the plasma CRP and SAA levels had decreased significantly by 2 weeks after the start of treatment (median 13 ν 0 µg/ml, range 7–92 µg/ml before
Cytokine profile during infliximab treatment

IFNγ and IL4 secretion of PBMC, stimulated by PHA, increased in the patients with RA during the 6 week period of treatment (median 1513 v 14 190 pg/ml, p < 0.0001 for IFNγ and median 23 v 42 pg/ml, p = 0.044 for IL4) (figs 1A and B).

In patients with RA the IFNγ secretion of PBMC had already increased after 2 weeks of treatment (median 1513 v 10 780 pg/ml, p = 0.001) and increased further between 2 and 6 weeks (median 10 780 v 14 190 pg/ml, p = 0.022) (fig 1A). The IFNγ and IL4 secretion of PHA stimulated PBMC increased also in the patients with other arthritides during the first 2 weeks of treatment (median 3753 v 4473 pg/ml, p = 0.043 for IFNγ and median 27 v 54 pg/ml, p = 0.043 for IL4).

No differences during the 6 weeks’ follow up were seen in the concentration of PHA stimulated IL5 or TNFα secretion by PBMC from patients with infliximab treatment (data not shown). No differences in the PHA stimulated cytokine secretion of PBMC were found in healthy controls in the samples taken 2 weeks apart (data not shown).

The ratio of IFNγ/IL4 mRNA in PHA stimulated PBMC increased during treatment in both patient groups. An increase between 0 and 6 weeks was significant in patients with RA (median 0.2 v 1.5, range 0–13 before treatment and 0–15 6 weeks after, p < 0.0001) and for patients with other arthritides (median 0.1 v 1.0, range 0–0.3 before treatment and 1–2 6 weeks after, p = 0.043). No changes were seen in the control subjects.

In patients with RA the TNFα mRNA levels increased during treatment, the increase between 2 and 6 weeks being significant (median 260 v 752, range 0–2784 at 2 weeks and range 86–2784 at 6 weeks, p = 0.009). No changes in the TNFα mRNA levels were seen in patients with other arthritides or in healthy controls (data not shown).

Chemokine receptor profile during infliximab treatment

In patients with RA the number of CD4 T cells and CD14 monocytes expressing CCR3 increased during treatment. The number of CD4 T cells expressing CCR3 increased between 0 and 2 weeks (median 0.4 v 0.8, p = 0.028) and between 0 and 6 weeks (median 0.4 v 0.6, p = 0.013) (fig 2A). The number of CD14 monocytes expressing CCR3 increased between 0 and 6 weeks (median 0.9 v 2.4, p = 0.009) (fig 2B). No changes in the expression of CCR3 on CD8 T cells were seen during the follow up period in patients with RA.

In patients with RA the expression of CCR5 on CD8 T cells increased during the treatment, the increase between 2 and 6 weeks being significant (median 0.13 v 0.2, p = 0.040) (fig 2C). No changes were seen in the expression of CCR5 on CD4 T cells or monocytes during the follow up period.

In patients with other arthritides no changes in the expression of CCR5 or CCR3 on T cells or monocytes was seen during the follow up period. In healthy controls the expression of CCR5 on monocytes decreased during the 2 week follow up (median 0.7 v 1.0, range 0–2 at 0 weeks and range 0–1 at 2 weeks, p = 0.017).

Markers associated with responsiveness to the treatment

The effect of treatment was determined at 2 weeks’ follow up before the second infusion of TNFα blocking agent.

The number of CD8 T cells expressing CCR3 was higher before the start of treatment in non-responders than in responders (median 0.3 v 0.1, p = 0.022) (fig 3A).

The number of CD4 T cells expressing CCR3 and CCR5 was higher in patients not responding to treatment than in the responders throughout the follow up period. The difference between non-responders and responders was significant before the start of treatment for CCR5 (median 0.2 v 0.1, p = 0.013) (fig 3B) and after 6 weeks of treatment for CCR3 and CCR5 (median 1.5 v 0.3, p = 0.020 and median 0.3 v 0.1, p = 0.029, respectively). Also before the start of treatment a similar trend was seen for CCR3 (median 0.5 v 0.3, p = 0.053) (fig 3C).

In patients with RA the number of CD3 T cells increased in patients responding to treatment and such a change was not seen in non-responders. When the change in the number of CD3 T cells during treatment was compared, the responders and non-responders differed (p = 0.001) (figs 4A and B). No significant differences in other immunological measures

Figure 1 Effect of infliximab on the secretion of IFNγ (A) and IL4 (B), studied with an ELISA, from PHA stimulated PBMC in patients with RA. The median values are indicated with horizontal lines.
between responders and non-responders were seen (data not shown).

**DISCUSSION**

At entry, the patients with RA showed impaired cytokine secretion of PBMC in response to PHA stimulation in comparison with controls, suggesting decreased peripheral T cell function as reported earlier. The TNFα blockade normalised the mitogen response of PBMC as shown by the normal production of both IFNγ and IL4. Activation of type I

![Figure 2](image1.png)

**Figure 2** Effect of infliximab treatment on the percentage of (A) CD4 T cells expressing CCR3; (B) CD14 gated monocytes expressing CCR3; and (C) CD8 T cells expressing CCR5 collected from CD3 gate and studied with flow cytometry in patients with RA. The median values are indicated with horizontal lines.

![Figure 3](image2.png)

**Figure 3** The percentage of CD8 (A) and CD4 (B, C) T cells expressing CCR3 (A, C) and CCR5 (B), studied with flow cytometry, before the start of treatment in patients with RA who responded and did not respond to the treatment. The median values are indicated with horizontal lines.

![Figure 4](image3.png)

**Figure 4** Change in the number of CD3 T cells (A, B) during infliximab treatment studied with flow cytometry in patients with RA responding (A) and not responding (B) to treatment. A comparison of the number of T cells between the groups showed a significant difference (p = 0.001).
immune response, described as an increase in the number of PBMC spontaneously producing IFN-γ after 4 weeks of treatment with etanercept, a soluble TNF receptor, has been reported earlier by Berg et al.23 Also, IFN-γ production of PBMC stimulated with microbial antigens (purified protein derivative, influenza virus) or autoantigen (collagen type II) increased in the patients during treatment. No increase in the mitogen-stimulated IFN-γ production was found, but instead, an increase in the secretion of IL-2 was seen. Increased secretion of IL-2 and IFN-γ has also been reported in patients with spondyloarthropathy receiving infliximab.24 As a conclusion, these studies together with our study suggest that recovery of impaired T cell response is associated with TNF-α blocking. In our study, we also found an increase in the type 2 associated cytokine secretion after PHA stimulation in patients receiving infliximab. However, our observation of an increase in the IFN-γ/IL-14 mRNA ratio, stimulated by PHA, suggests a more pronounced effect on type 1 immunity.

It has been reported that the chronic overproduction of TNF-α suppresses T cell functions,25 and thus elimination of excess TNF-α in patients receiving TNF-α blocking agent results in recovery of T cell responses. These findings of enhanced Th1 immunity as a response to TNF-α blocking challenge the paradigm of pathogenicity of Th1 cells in RA, as discussed also in the context of spondyloarthropathy.26 Possibly, the recovery of T cell function is associated with the recovery of regulatory mechanisms, and the impaired peripheral T cell function may fundamentally be associated with autoimmunity.

We found that the number of T cells and monocytes expressing CCR3 and CCR5 increased as response to treatment in patients with RA. This indicates activation of peripheral T cells and is in accordance with the increase in the mitogen-stimulated cytokine response observed. It is also possible that the increase in the number of CCR3 and CCR5 expressing cells reflects the decreased accumulation of inflammatory cells from the periphery to inflamed joints, as suggested previously.27 In patients with other arthritides we found no change in the expression of chemokine receptors during treatment. This might be due to the small number and heterogeneous disease pattern among the patients studied.

It has been reported that TNF-α decreases expression of CCR5 in peripheral blood monocytes and alveolar macrophages by production of the CCR5 ligand, RANTES.28 Down regulation of CCR5 as a response to TNF-α is detected also on dendritic cells.29,30 Hornung et al reported that TNF-α affects CCR5 expression on peripheral blood lymphocytes.31 They showed that TNF-α down regulates the expression of CCR5 on previously activated peripheral blood lymphocytes and delays the expression of CCR5 on the cells early in the activation process. Also, CCR3 is down regulated by TNF-α as shown by Sato et al.32 Thus, the increase in CCR3 and CCR5 expression on T cells and monocytes can be explained by a rebound effect due to blocking of TNF-α.

When patients with RA were divided into responding and non-responding groups according to ACR20 criteria, the patients responding to treatment had a lower numbers of T cells expressing CCR3 and CCR5 before the start of infusions than the non-responders. High levels of CCR3 and CCR5 on CD4 and on CD8 positive T cells were thus predictive markers of a poor effect of treatment. This suggests that the activation of peripheral T cells is an important mechanisms in TNF-α blocking and, possibly, this treatment is most effective in those patients with impaired peripheral T cell function, because the excess TNF-α also causes down regulation of chemokine receptors. The high levels of CCR3 and CCR5 on the T cells of patients not responding to infliximab might indicate that in these patients the activity of RA is more dependent on other inflammatory mediators and less on TNF-α.

It has been reported that patients with RA have a greater number of TNF-α-producing PBMC both before and after treatment with TNF-α blocking agents than healthy controls, and no effect on the number cells spontaneously producing TNF-α during TNF-α treatment is seen.33 In our study treatment increased the expression of TNF-α at the mRNA level, probably owing to positive feedback mechanisms, but no effect at the protein level was seen as PHA stimulated secretion of TNF-α did not change during treatment in patients with RA.

Some reports show that the number of circulating lymphocytes is transiently increased after monoclonal anti-TNF-α antibody treatment in a dose dependent fashion.25 In response to treatment, the number of T cells increased and the CRP levels decreased in the patients who showed good clinical response in our study, but no changes in T cells were seen in the patient group as a whole. Our results suggest that changes in T cell number and CRP are related to the effect of treatment.

In conclusion, the TNF-α blocking treatment seems to activate the cell mediated immune system to compensate or to rebalance itself. Increase in the induced production of both type 1 and type 2 cytokines, together with the increase in the number of T cells and monocytes expressing CCR3 and CCR5, suggests that recovery of peripheral T cell function is associated with the clinical effects of TNF-α blocking. This treatment seems to be most effective among those patients with RA who have decreased expression of chemokine receptors on peripheral T cells before the start of treatment.

ACKNOWLEDGEMENTS

The authors are indebted to Ms Arja Kaarto for her excellent organising skills and to Ms Anneli Suomela, Mr Harry Lybeck, and Ms Maria Kiikkeri for their excellent technical assistance. This study was supported by grants from the Instrumentarium Research Foundation, Rheumatism Foundation Hospital, Academy of Finland, and the Finnish Cultural Foundation.

Authors’ affiliations

R Nissinen, O Vaarala, Department of Molecular Medicine, National Public Health Institute, Helsinki, Finland

R Nissinen, T Palosuo, Department of Health and Functional Capacity, National Public Health Institute, Helsinki, Finland

M Leirisalo-Repo, R Peltomaa, Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, Helsinki, Finland

O Vaarala, Division of Paediatrics, Department of Molecular and Clinical Medicine, Linköping University, Linköping, Sweden

REFERENCES


8. Fong Y, Tracey KJ, Moldawer LL, Hesse DG, Manogue KB, Kenney JS, et al. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and...
Infliximab induced CCR and cytokine profile

Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis
R Nissinen, M Leirisalo-Repo, R Peltomaa, T Palosuo and O Vaarala

Ann Rheum Dis 2004 63: 681-687
doi: 10.1136/ard.2003.008599

Updated information and services can be found at:
http://ard.bmj.com/content/63/6/681

These include:

References
This article cites 24 articles, 8 of which you can access for free at:
http://ard.bmj.com/content/63/6/681#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Immunology (including allergy) (5144)
- Connective tissue disease (4253)
- Degenerative joint disease (4641)
- Musculoskeletal syndromes (4951)
- Rheumatoid arthritis (3258)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/